Astrazeneca Pharma India Ltd Share Price (ASTRAZEN)

AstraZeneca Receives Permission for New Drug Import - 22 Nov, 2023

AstraZeneca Pharma India Ltd has received permission to import pharmaceutical formulations of a new drug, Olaparib (Lynparza), for sale or distribution in Form CT-20 from the Central Drugs Standard Control Organisation.

AstraZeneca Pharma India to Exit Manufacturing at Bangalore Plant - 17 Nov, 2023

AstraZeneca Pharma India will be exiting manufacturing at its only plant in Bangalore as part of a global strategic review. The company plans to transfer core manufacturing functions to a contract manufacturer and focus more on research and development in Bangalore, as well as establish an IT and global capability center in Chennai.

AstraZeneca Plans to Sell Manufacturing Site in Bangalore - 16 Nov, 2023

AstraZeneca Pharma India Ltd plans to sell its production facility in Bengaluru as part of a strategic review of global manufacturing and supply network by its parent company.

Legal Challenge Overshadows AstraZeneca Pharma India's Strong Q2 Performance - 10 Nov, 2023

AstraZeneca Pharma India reported a strong Q2 performance with a 60.8% YoY growth in profit, but its shares fell over 3% due to a legal challenge faced by the parent firm's COVID-19 vaccine in the UK.

AstraZeneca India Aims to Eliminate Lung Cancer - 01 Nov, 2023

The Managing Director of AstraZeneca India has expressed the company's goal to eliminate lung cancer as a cause of death.

Astrazeneca Pharma India Sets New One-Year High - 10 Oct, 2023

Astrazeneca Pharma India Ltd was among the notable companies to set a new one-year high on October 10, 2023.

Astrazeneca Pharma India Ltd Stock Bullish - 08 Oct, 2023

The stock experienced selling pressure near the resistance zone but closed strong with a bullish green candle after breaking out. Good buying pressure and fundamentals indicate growth potential, with targets of Rs 5093 and Rs 5190.

AstraZeneca Pharma India's Stock Sees Significant Increase - 07 Oct, 2023

Over the past three months, AstraZeneca Pharma India's stock has increased by 26%. The company's ROE is higher than industry average and it has seen decent growth over the last five years. It retains most of its profits for reinvestment but has paid dividends for four years.

Bhavana Agrawal appointed as CFO of AstraZeneca Pharma India - 03 Oct, 2023

AstraZeneca Pharma India appoints Bhavana Agrawal as the new Chief Financial Officer. The USFDA inspected Unit VI-B and issued one procedural observation.

Fitch Ratings Report Boosts Indian Pharma Companies - 24 Aug, 2023

A Fitch Ratings report stated that government guidelines mandating physicians prescribe only generic drug names face execution challenges and are unlikely to impact the profitability of pharmaceutical companies in the domestic market, providing a boost for Indian pharma companies.

Astrazeneca Pharma India Ltd is Overbought with Bearish RSI Trends - 18 Aug, 2023

According to reports, Astrazeneca Pharma India Ltd is one of the 10 overbought stocks with bearish RSI trends.

AstraZeneca Launches Pediatric Drug in India - 10 Aug, 2023

AstraZeneca Pharma India has launched Selumetinib (Koselugo), a pediatric drug for the treatment of neurofibromatosis type 1, and will hold a board meeting on August 14 to approve Q1 results.

Astrazeneca Pharma India Receives Approval for Heart Failure Drug Import and Achieves 52-Week High - 25 Jul, 2023

AstraZeneca Pharma India has received approval from the Drugs Controller General of India to import heart failure treatment drug Dapagliflozin tablets. The company also achieved a new milestone with a 52-week high of Rs 3,882.70.

AstraZeneca Receives Approval for Heart Failure Treatment Drug - 24 Jul, 2023

AstraZeneca Pharma India has received approval from the Drugs Controller General of India to import Dapagliflozin tablets for the treatment of heart failure in adults, paving the way for launch subject to related approvals and licenses.

AstraZeneca Pharma India Increases Dividend Payment - 06 Jul, 2023

AstraZeneca Pharma India Limited has increased its dividend payment to ₹16.00, up from last year's payment of the same period. However, the yield remains low at only 0.4%. The company has solid earnings coverage and is paying more than 75% of its free cash flow to shareholders.

Astrazeneca Pharma India Ltd sees stock price breakout and growing business - 16 Jun, 2023

Astrazeneca Pharma India Ltd's stock price broke out of a 7-month consolidation phase and could reach 4000 levels in a month. The company has a growing business with good EPS growth and EBIT margins up to 15%.